Navigation Links
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Date:5/28/2009

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;

Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers

SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID), a First-in-Human Phase 1/2 Clinical Trial, in a scientific symposium at the 12th Annual American Society of Gene Therapy Meeting.

The Phase 1 data showed that MYDICAR(R) had an acceptable safety profile in twelve patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months were observed across a number of key efficacy parameters important in assessing heart failure status. Efficacy was defined as the mean improvement in at least 2 of 5 domains without any worsening in the remaining domains, including a functional six-minute walk test, oxygen consumption, quality of life questionnaire, biomarker activity and left ventricular size and function.

"We are encouraged by the meaningful improvements in cardiac function and overall condition of patients, findings that we believe demonstrate the return toward normal intracellular calcium cycling and contractility in some of the heart muscle cells of these very sick patients," said Krisztina M. Zsebo, Ph.D., president and chief executive officer. "Our extensive preclinical and clinical investigation to understand the molecular basis of myocardial dysfunction, together with the evolution of safe and efficient gene transfer technology, has placed gene-based therapy for heart failure within reach and yielded valuable insights for the entire field of study."

The Phase 1 open-label, sequential dose escalation, multi-center phase of the trial was designed to investigate safety and biological effects of restoring SERCA
'/>"/>

SOURCE Celladon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
2. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
3. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
4. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
5. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
6. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
7. USAID Provides $5M in Emergency Support as Swine Flu Spreads
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 P&S ... with market overview, trends, DRO analysis, market ... recent developments, competitive scenario and top competitor ... Biosensors Market Development and Demand Forecast to ... ) Explore more about global ...
(Date:7/30/2015)... 30, 2015 Global ENT ... to reach USD 23.01 million in 2022, according to ... base of geriatric population, increasing prevalence of ear, nose, ... of awareness among target customer base are expected serve ... forecast period. According to estimates published by the WHO, ...
(Date:7/30/2015)... July 30, 2015  Lannett Company, Inc. (NYSE: ... at the Canaccord Genuity 35th Annual Growth Conference on ... the InterContinental Boston Hotel.  A webcast ... .  Listeners are encouraged to visit the web site ... the presentation to register, download and install any necessary ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... the World,s First Generic Pirfenidone in India, Giving Hope to... -- MUMBAI, India, October 20, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... Va., Oct. 20 Medmarc Insurance , ... medical device and life sciences industry, launched today the ... visitors to its website with leading industry product and ... the Network is available to everyone that visits ...
Cached Medicine Technology:Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 2Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 3Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 4Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 5Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 6Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 7Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 8Medmarc Business Network Launched - Saving Medical Device and Life Sciences Manufacturers Time & Money 2
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... On July 23rd ... billion in taxpayer money to fund the state’s large prison system, which has amassed ... the highest rates of incarceration. In light of President Obama’s recent reduction of non ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Association of ... announcement of the reinstitution of National Prescription Drug Take-Back Days. The 10th event ... AM to 2:00 PM local time. On the 26th, the DEA, with the ...
(Date:7/30/2015)... Irvine, CA (PRWEB) , ... July 30, 2015 , ... ... applications offers a new bird hazing system to repel pest birds from ... of 60 diseases—including histoplasmosis, encephalitis, salmonella, meningitis, and toxoplasmosis, even the West Nile virus. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry eye season, especially in ... particularly long, dry and hot 2015 summer season and the dry eye rate in ... Kleyne will discuss the 2015 summer season and identify the primary dry eye hot ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... New Survey Indicates that a Patient,s or Loved One,s Hearing ... to Inefficiency and ... Hearing loss among those,who require the assistance of a caregiver ... providing care, according to a new survey,released by Songbird Hearing, ...
... Winners Can Receive Up to $15,000 Each to Donate to Nonprofit of Their ... ... The deadline to submit,nominations for this year,s Welcome Back Awards, a national awards ... are now due by Monday, December 15, 2008., The Welcome Back Awards ...
... Calif., Nov. 12 Forterus,Inc. (OTC Bulletin Board: FTER) ... back up to $20,000 in stock in open market,transactions., ... is severely,undervalued, and does not reflect the financial success ... past two months," said,Paul Howarth, CEO of Forterus., ...
... Study Links Quercetin To Reduced Risk for Respiratory Infection, ... for a natural,way to stay well this cold and ... of today,s hottest "Super Fruits." In conjunction with,the typical ... known for its natural anti-viral activity and found in ...
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... diseases,reported corporate and clinical program updates for the ... The updates were given during,a podium presentation by ... web,cast at the Rodman & Renshaw 10th Annual ...
... of the Place They Live , ... Alpharetta, Ga. (Vocus) November 12, ... headquarters on October 17, 2008. The building houses the six operating ... Associates had significant input into the design of the building from ...
Cached Medicine News:Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 2Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 4Health News:Deadline Extended to Submit Nominations for Depression Awards Program 2Health News:Deadline Extended to Submit Nominations for Depression Awards Program 3Health News:Forterus Inc. Announces Stock Buyback 2Health News:New Research Shows Specific Antioxidant, Found in Cherries, May Boost the Body's Defenses Against the Flu 2Health News:EntreMed Reports Clinical Program Progress and Company Update 2Health News:EntreMed Reports Clinical Program Progress and Company Update 3Health News:EntreMed Reports Clinical Program Progress and Company Update 4Health News:EntreMed Reports Clinical Program Progress and Company Update 5Health News:Jackson Healthcare Dedicates New Corporate Headquarters 2Health News:Jackson Healthcare Dedicates New Corporate Headquarters 3
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: